BNC210: An Novel, Investigational Treatment for Stress and Anxiety Disorders with acute and chronic symptomatic effects

BNC210 is a a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR).

Extensive research on animals and human subjects has demonstrated that BNC210 possesses a distinctive mechanism of action, making it a promising candidate for treating a variety of conditions such as SAD, PTSD, and other neuropsychiatric disorders.

Based on clinical trial data to date, BNC210 has been observed to have several advantages over the drugs currently used to treat anxiety, depression, and PTSD (SSRIs, SNRIs, and benzodiazepines) including:

• Combined anxiolytic and antidepressant clinical effects
• Fast acting onset of action following acute or chronic administration
• No evidence of adverse events related to sedation, memory or motor impairment
• No evidence for habit formation or increased risk of suicidality